Overview

Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

Status:
Completed

Trial end date:
2011-02-01

Target enrollment:

Participant gender:

Summary

This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.

Phase:

Phase 2

Details

Lead Sponsor:

Reata Pharmaceuticals, Inc.